AB SCIENCE Paris, 31 October 2014, 5:45 Pm
Web conference
Masitinib in mastocytosis - current status and perspectives
7 November 2014 (17h45 - 18h45 CET)
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web conference on masitinib in the treatment of mastocytosis with key opinion leaders from this disease.
The web conference call will be held on 7 November 2014 from 17h45 to 18h45 CET.
The web conference will provide the opportunity to understand:
- The different forms of mastocytosis, both in adults and children, and what forms can be pursued with masitinib
- What is mast cell activation syndrome (MCAS), a much more common disease, and how masitinib could be developed in this indication
- The current results from masitinib in mastocytosis, the phase 3 design and primary endpoint for efficacy analysis, and the perspectives for phase 3 read-out
- The market potential for masitinib in mastocytosis and in mast cell activation syndrome (MCAS)
It will be followed by a Q&A session.
The following experts in this disease will animate the discussion and answer questions
- Dr. Lawrence B. Afrin
Division of Hematology, Oncology & Transplantation
University of Minnesota Medical Center, Minneapolis, USA
- Dr. Karin Hartmann
Department of Dermatology and Venereology
University Hospital of Cologne, Germany
- Pr. Olivier Hermine
Division of Hematology/Oncology
Necker University Hospital, Paris, France
- Dr Marek Niedoszytko
Department of Allergology
Medical University of Gdansk, Poland
- Dr. Frank Siebenhaar
Department of Dermatology and Allergy
Allergie-Centrum-Charite / ECARF
Charité - Universitätsmedizin Berlin, Germany
The presentation supporting this conference call will be made available on AB science web site upon completion of the web call.
About masitinib
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in human and animal health.
AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing thirteen phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).
Further information is available on AB Science's website: www.ab-science.com
This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.
* * *
AB Science - Financial Communication & Media Relations
contact@ab-science.com
http://hugin.info/155655/R/1867712/656318.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AB Science via Globenewswire
